Applied Tissue Technologies’ negative-pressure dressing gets FDA nod

Wound-care company Applied Tissue Technologies said it has won FDA clearance of its negative-pressure wound therapy product, the Platform Wound Dressing (PWD). The class II device represents the first-of-its-kind embossed negative pressure wound therapy device to be used without foam or gauze, according to the Hingham, Mass. company.

The PWD is a transparent dressing with an integral adhesive base and a permanently embossed, impermeable membrane that combines the traditional functions of the negative-pressure wound therapy membrane and foam/gauze in currently marketed negative-pressure devices. When the negative-pressure pump is switched on, the embossed membrane is pulled into direct contact with all geometries of the wound, eliminating the need for foam or gauze. The space created between the embossments provides primary channels for air and fluid, while folds in the membrane create secondary channels that provide an even distribution of negative pressure across the wound.

“The PWD represents a true innovation in wound healing technology,” said Applied Tissue CEO Michael Broomhead in a prepared statement. “Our company is committed to novel research and developing new technologies in advanced wound care. We believe that the PWD with its embossed NPWT will have a major impact in healing patients’ wounds.”

Independent of this clearance, ATT has three ongoing clinical trials funded by the U.S. military to evaluate the PWD.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW